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Antitumor effectRecently, a polyethylene glycol (PEG)-modiﬁcation method for liposomes prepared using pH-gradient method
has been proposed. The differences in the pharmacokinetics and the impact on the antitumor effect were exam-
ined; however the impact of PEG-lipid molar weight has not been investigated yet. The main purpose of this
study is to evaluate the impact of PEG-lipid molar weight against the differences in the pharmacokinetics, the
drug-release proﬁle, and the antitumor effect between the proposed PEG-modiﬁcation method, called the
post-modiﬁcationmethod, and the conventional PEG-modiﬁcationmethod, called the pre-modiﬁcationmethod.
Various comparative studies were performed using irinotecan as a general model drug. The results showed that
PEG-lipid degradation could be markedly inhibited in the post-modiﬁcation method. Furthermore, prolonged
circulation time was observed in the post-modiﬁcation method. The sustained drug-release was observed in
the post-modiﬁcation method by the results of the drug-releasing test in plasma. Moreover, a higher antitumor
effect was observed in the post-modiﬁcation method. It was also conﬁrmed that the same behaviors were ob-
served in all comparative studies even though the PEG molecular weight was lower.
In conclusion, the post-modiﬁcationmethodhas the potential to be a valuable PEG-modiﬁcationmethod that can
achieve higher preservation stability of PEG-lipid, prolonged circulation time, and higher antitumor effect with only
half the amount of PEG-lipid as compared to the pre-modiﬁcation method. Furthermore, it was demonstrated that
PEG5000-lipid would be more desirable than PEG2000-lipid since it requires much smaller amount of PEG-lipid to
demonstrate the same performances.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Currently, drug delivery system studies focus on achieving selec-
tive delivery and distribution of drugs to the target disease sites to
enhance safety and effectiveness. Therefore, the feasibility of various
types of particulate systems such as liposomes, emulsions, and poly-
meric nanoparticles has been evaluated as effective drug delivery
systems [1–3].
To selectively deliver an encapsulated drug to the target site, the
control of its pharmacokinetics is essential. The clearance of liposomes
has been considered to occur through their capture by themononuclear
phagocyte system (MPS), which takes up liposomes circulating in the
blood stream and removes them. It is especially important to avoid cap-
ture by the phagocytic cells in the liver and spleen to prolong circulation
time in the blood. Various liposome characteristics affect circulation
time in the blood, such as lipid composition, size, and Zeta-potential
[4–6]. Among these, liposome membrane surface modiﬁcation usingai-machi, Ashigarakami-gun,
: +81 465 81 4114.
oshino).
rights reserved.monosialoganglioside GM1 or polyethylene glycol (PEG)-conjugated
lipid (PEG-lipid) has been shown to greatly improve the pharmacoki-
netics [7,8]. PEG is a highly hydrophilic polymer with very low toxicity;
hence, PEG and its derivatives have been widely used to improve the
stability and pharmacokinetics of drug carriers and parent drug [9]. In
liposomal drug delivery, PEG-lipid has been widely used for liposome
surface modiﬁcation, and this technique, called PEGylation, has been
already employed in the preparation of liposomal drug delivery sys-
tems, which are known as PEGylated liposomes [10–23]. Speciﬁcally,
doxorubicin-loaded PEGylated liposomes (Doxil®) have a strong phar-
macological effect and low toxicity. Therefore, these have been widely
used in clinical applications and approved in more than 80 countries
for the treatment of cancer [24,25]. To manufacture this product, a
unique technology known as the pH-gradientmethod has been utilized
to achieve high drug-loading efﬁciency [26–29].
To achieve the prolonged circulation time using PEGylated lipo-
somes, it is important to maintain the physiological and physico-
chemical stabilities of the PEG-lipid. To our knowledge, however,
excess PEG-lipid degradation has been observed; especially in the
PEGylated liposomes prepared using the pH-gradient method. Owing
to the pH-gradient method, the pH of the internal aqueous phase
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general, phospholipids are a component of PEG-lipid, and this group is
easily hydrolyzed in a bell-shaped manner, with the greatest stability
at around neutral pH [30]. Our recent research demonstrated that the
post-modiﬁcation method could markedly inhibit PEG-lipid degrada-
tion and prolong the circulation time [31]. Recently, the differences in
the pharmacokinetics and the impact on the antitumor effect were ex-
amined using vinorelbine, which is vinca alkaloid group, as a model
drug [32]. However, the impact of PEG-lipid molar weight has not been
investigated yet.
In this study, we selected irinotecan (CPT-11) as a general model
drug instead of vinorelbine since it shows extremely fast drug-release
proﬁles due to its high hydrophobicity [33]. In addition, the liposomal
CPT-11 showed a great feasibility as the drug delivery system with
less toxicity and high pharmacological effect [34]. We demonstrated
various comparative studies with CPT-11 liposomes prepared using
the proposed PEG-modiﬁcation method, called the post-modiﬁcation
method [35], and the conventional PEG-modiﬁcation method, called
the pre-modiﬁcationmethod. Themain purpose of this study is to eval-
uate the impact of PEG-lipid molar weight against the differences in the
pharmacokinetics, the drug-release proﬁle, and the antitumor effect be-
tween thepre- and post-modiﬁcationmethods using CPT-11 liposomes.
2. Material and methods
2.1. Materials
Hydrogenated soy phosphatidylcholine (HSPC) was purchased from
Lipoid GmbH (Ludwigshafen, Germany), cholesterol (Chol) was obtained
from Dishman (Veenendaal, Netherlands). Methoxypolyethyleneglycol
(Mw: 2000)-distearylphosphatidylethanolamine (PEG2000-lipid).
Methoxypolyethyleneglycol (Mw: 5000)-distearylphosphatidyle-
thaxnolamine (PEG5000-lipid) was purchased from NOF (Tokyo,
Japan). Irinotencan hydrochloride (CPT-11) was obtained from
Yakult Honsha. (Tokyo, Japan). All other chemicals used were of
analytical grade.
Rats (Crl:CD (SD), male, 7 weeks old) for pharmacokinetics experi-
ments and BALB/c nude mice (CAnNCg-Foxnlnu/CrlCrlj, male, 5 weeks
old) for antitumor effect experiments were purchased as test animals
from Charles River Japan, Inc. (Yokohama, Japan). Human colon cancer
cells (HT-29) were purchased from American Type Culture Collenction
(ATCC).
2.2. Preparation of CPT-11 liposomes by the pre- and post-modiﬁcation
methods
Our recent studydemonstrated that PEG5000-lipid could be distributed
only on the outer surface of the liposomes in the post-modiﬁcationmeth-
od, whereas it was equally distributed both on the inner and outer sur-
faces in the pre-modiﬁcation method [31,36]. CPT-11 liposomes were
prepared using the above 2 different PEG‐modiﬁcation techniques.
2.2.1. Preparation of CPT-11 liposomes by the pre-modiﬁcation method
(Pre)
PEGylated liposomes composedofHSPC, Chol (molar ratio, 54:46) and
1.5 mol% of PEG5000-lipid were prepared as follows. HSPC (7.06 g), Chol
(2.94 g) and PEG5000-lipid (1.51 g)were dissolved in dehydrated ethanol
(10 ml) at 72 °C and hydrated in 250 mM aqueous solution of ammoni-
um sulfate (90 ml) for 10 min at 72 °C to afford crude liposomes. The
obtained crude liposomes were ﬁrstly ﬁltered through 200 nm of double
ﬁlters three times using Extruder T100. After this, the particle size was
further regulated through 100 nm of ﬁlters until the particle size came
to approximately 100 nm [PEGylated liposomes (Pre)].
The outer aqueous solution of PEGylated liposomes was ex-
changed with 10% sucrose and 10 mM histidine (pH 6.5) using cross
ﬂow to generate pH-gradient between outer and inner aqueous solution(pH-gradient liposomes). An aqueous CPT-11 solution was added to
pH-gradient liposomes at CPT-11/total lipid weight ratio of 0.18 and in-
cubated at 50 °C for 20 min. Unloaded CPT-11was removed using cross
ﬂow with 10% sucrose and 10 mM histidine solution (pH 6.5) as an el-
uent. Finally, sterile ﬁltration using a 0.2-μmmembrane ﬁlter (Minisart
Plus, Sartorius, Goettingen, Germany) was carried out for PEGylated li-
posomes encapsulated with CPT-11 [CPT-11 liposomes (Pre)]. CPT-11
liposomes (Pre) containing 4.0 mol% of PEG2000-lipid was prepared
using the same method.
2.2.2. Preparation of CPT-11 liposomes by the post-modiﬁcation method
(Post)
Bare liposomes composed of HSPC and Chol (molar ratio, 54:46)
were prepared as follows. HSPC (21.17 g) and Chol (8.83 g) were
dissolved in dehydrated ethanol (30 ml) at 72 °C and hydrated in
250 mM aqueous solution of ammonium sulfate (270 ml) for 10 min at
72 °C to afford crude liposomes. The obtained crude liposomeswere ﬁrst-
ly ﬁltered through 200 nm of double ﬁlters three times using Extruder
T100. After this, the particle size was further regulated through 100 nm
of ﬁlters until the particle size came to approximately 100 nm. Then, a
60 ml of PEG5000-lipid aqueous solution (37.67 mg/ml) was added to
the liposome suspension and heated at 65 °C for 30 min to afford
PEGylated liposomes with 0.75 mol% of PEG5000-lipid [PEGylated lipo-
somes (Post)].
The same process described in Section 2.2.1 was then conducted. Fi-
nally, sterileﬁltration using a 0.2-μmmembraneﬁlter (Minisart Plus, Sar-
torius, Goettingen, Germany) was carried out for PEGylated liposomes
encapsulated with CPT-11 [CPT-11 liposomes (Post)]. CPT-11 liposomes
(Post) containing 2.0 mol% of PEG2000-lipidwas prepared using the same
method.
2.3. Characterization of CPT-11 liposomes
2.3.1. Determination of the lipid component
HSPC, Chol, and PEG-lipid were analyzed by HPLC [31]. Brieﬂy,
Each CPT-11 liposomes (Pre and Post) (2 ml) was dissolved in a mix-
ture of water, chloroform, 2-propanol, and internal standard solution.
Standard solutions of HSPC, Chol, and PEG-lipid were prepared sepa-
rately. The lipid component of the prepared solutions (30 μl) was deter-
mined using the following HPLC conditions: column, Inertsil Ph column
(4.6×250 mm, 5 μm; GL Science, Japan); mobile phase, acetate buff-
er/methanol/ethanol; detector; refractive index detector (Shimadzu,
Japan); and ﬂow rate, approximately 1 ml/min.
The PEG-modiﬁcation ratio was calculated according to the fol-
lowing formula:
PEGmodification ratio mol%ð Þ ¼measured PEG lipid molð Þ
=½measured HSPC molð Þ
þmeasuredChol molð Þ  100
2.3.2. Determination of CPT-11 concentration
Each CPT-11 liposomes (Pre and Post) (0.4 ml) were dissolved in
a mixture (9.6 ml) of internal standard solution and methanol. 2 ml
of above sample was taken and further dilution by mixture (18 ml)
of phosphate solution and methanol. A small aliquot (10 μl) of the
test solution was applied to an HPLC system (Shimadzu, Kyoto, Japan)
equipped with an Inertsil ODS-2 column (4.6×250 mm, 5 μm, GL
Science, Tokyo, Japan) and UV detector at 254 nm. The mobile phase
was a mixed solution of acetonitrile, formic acid, methanol, and water.
2.3.3. Other methods
Particle size and Zeta-potential were determined using Zetasizer
3000HS (Malvern Instruments, UK). To measure particle size (nm),
20 μl of liposomes was diluted with 3 ml of physiological saline
Table 1
Characterization of prepared CPT-11 liposomes.
PEG-modiﬁcation
method
Mw HSPC:
Chol:PEG
(molar
ratio)
PEG-lipid
content
(mol%)
Diameter
(nm)
Zeta‐
potential
(mV)
CPT-11
content
(mg/ml)
Pre 5000 54:46:1.5 1.48 102 −12.5 5.03
Post 5000 54:46:0.75 0.75 114 −12.7 5.08
Pre 2000 54:46:4.0 4.0 97 −27.8 5.00
Post 2000 54:46:2.0 2.0 107 −26.5 4.92
Pre: pre-modiﬁcation method, Post: post-modiﬁcation method.
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puriﬁed water to measure Zeta-potential.
2.4. Various comparative studies of CPT-11 liposomes
2.4.1. Accelerated preservation stability experiments
Each CPT-11 liposomes (Pre and Post) was stored at 25 °C and 60%
RH to measure PEG-lipid (PEG5000-lipid or PEG2000-lipid) and HSPC re-
sidual ratio after predetermined periods (4, 8 and 12 weeks). PEG-lipid
(PEG5000-lipid or PEG2000-lipid) and HSPC amounts were measured
using HPLC system and each residual ratio were calculated.
2.4.2. Pharmacokinetics experiments
Each CPT-11 liposomes (Pre and Post) was intravenously adminis-
tered via tail vein of a rat [Crl: CD (SD), male, 7 weeks old] as a dose of
30 mg/kg equivalent of CPT-11 (n=6 or 5). At 1, 2, 4, 8, 24, 48 and
72 h after administration, 0.3 ml of blood plasma was obtained by
centrifuge (15,000 rpm, 3 min, 0 °C). 0.1 ml of obtained supernatant
was diluted with 0.4 ml of 0.15 H3PO4 solutions. After diluting 0.1 ml
of the diluted blood plasma with 0.4 ml of methanol, the resultant
solution was treated in a centrifuge (15,000 rpm, 3 min, 0 °C). 0.1 ml
of obtained supernatant was diluted with 0.4 ml of an internal standard
solution (camptothecin 1 µg/ml in 0.15 M H3PO4), to thereby obtain a
sample for total CPT-11 concentration measurement. Analysis of phar-
macokinetics parameters was made using WinNonlin (Pharsight Inc.).
2.4.3. In vitro release experiments in blood plasma of rats
A laparotomy was performed on a rat (Crl: CD (SD), male, 7 weeks
old) under nembutal anesthesia for collection of whole blood from an
abdominal aorta of the rat. After adding 0.2 ml of heparin to the collect-
ed blood, the resultant solution was treated in a centrifuge (3000 rpm,
15 min, 4 °C), to thereby obtain supernatant (plasma). The obtained su-
pernatant was stored in frozen state under−20 °C. After thawing the
frozen blood plasma of the rat on the ice and preheating 0.5 ml of the
thawed blood plasma for 5 min at 37 °C, 5 μl of both CPT-11 liposomes
(Pre and Post) was added to begin the release experiments. At 0, 1, 2,
and 4 h after the incubation, 0.1 ml of the samplewas taken and diluted
with 0.4 ml of 0.15 H3PO4 solutions. After diluting 0.1 ml of the diluted
blood plasmawith 0.4 ml ofmethanol, the resultant solutionwas treated
in a centrifuge (15,000 rpm, 3 min, 0 °C). 0.1 ml of obtained supernatant
was diluted with 0.4 ml of an internal standard solution (camptothecin
1 µg/ml in 0.15 M H3PO4), to obtain a sample for total irinotencan
concentration measurement. Meanwhile, subjecting 0.2 ml of the
diluted blood plasma to centrifugal separation (100,000 g, for 30 min,
10 °C), and the obtained 0.05 ml in the upper layer was diluted with
0.2 ml of methanol, the resultant solution was treated in a centrifuge
(15,000 rpm, 3 min, 0 °C). 0.1 ml of obtained supernatant was diluted
with 0.4 ml of the internal standard solution, to obtain a sample for re-
leased irinotecan concentrationmeasurement. Then, each concentration
of total irinotecan and released irinotecan were measured using HPLC
system and ﬂuorescence detector. The encapsulated irinotecan concen-
trationwas calculated by subtracting the released irinotecan concentra-
tion from the total irinotecan concentration. The number of n used in
these release experiments was 3.
2.4.4. Antitumor effects in vivo
Human colon cancer cells (HT-29) were subcultured under the
condition of 5% CO2 and 37 °C by using Dulbecco's Modiﬁed Eagle's Me-
dium(DMEM) containing 10%heat-inactivated fetal bovine serum(FBS),
100 U/ml of penicillin and 100 μg/ml of streptomycin. 2×106 cells/
0.1 ml/mouse of HT-29 cells were implanted subcutaneously in left in-
guinal region of a nudemouse by using a glass syringe and injection nee-
dle. The groupwas separated so that a day inwhich a presumptive tumor
volume calculated by 1/2ab2 (a: represents a longitudinal diameter of a
tumor and b: represents a short axis diameter) achieved about
100 mm3 was set as day 0. At day 1, each CPT-11 liposomes (Pre andPost) (12.5 mg/kg/dose per) was intravenously administered. A physi-
ological saline solutionwhich is a solventwas administered for a control
group. After extracting tumors andmeasuring a weight at day 21, an in-
hibition rate of tumor growth (I.R.) (%) was calculated by the following
formula to determine a main effect. A presumptive tumor volume was
secondarily measured for the total comparison. Each group was
consisted of 10 mice.
I:R: %ð Þ ¼ ð1−average tumor weight in a treatment group=
average tumor weight in a control groupÞ  100
2.4.5. Ethics in animal experiments
All the in vivo experimental protocols were approved by the ani-
mal care committee of the Yakult Central Institute for Microbiological
Research.
2.4.6. Statistical analysis
For group comparisons, one-way analysis of variance (ANOVA)with
duplicationwas applied. Signiﬁcant differences in themeanvalueswere
evaluated by Student's unpaired t-test. A p value of less than 0.05 was
considered signiﬁcant.
3. Results and discussion
3.1. Chromatographic analysis of CPT-11 liposomes
Each CPT-11 liposomes prepared using the pre-and post-modiﬁcation
methods was analyzed by various equipments and the characteristics of
resultant liposomes, PEG-lipid content (PEG5000-lipid or PEG2000-lipid),
diameter, Zeta-potential, and CPT-11 content are listed in Table 1. As
seen in Table 1, the particle size with the post-modiﬁcation method was
slightly larger than that with the pre-modiﬁcation method. This behavior
is reasonable because in the pre-modiﬁcation method, the sizing process
is initiated after PEGylation; therefore, the ﬁnal particle size is adjusted to
the intended size, irrespective of the PEG-lipid content. On the other
hand, in the post-modiﬁcation method, the sizing process is initiated be-
fore PEGylation; therefore, the ﬁnal particle size means sum total of bare
liposomes and PEG layer thickness.
With respect to the Zeta-potential of the PEGylated liposomes, no
clear differences were observed between the pre- and post-modiﬁcation
methods in not only the PEG5000-lipid modiﬁed liposomes (−12 mV)
but also the PEG2000-lipid modiﬁed liposomes (−27 mV). This negative
charge density comes from the PEG-lipid itself, and is thought to be bal-
anced by the charge-shielding effect of PEG-chains. In principle,
PEG-chains of lowermolecule weight show smaller charge-shielding ef-
fect. This means that the apparent Zeta-potential would be lower in the
case of lower molecule weight PEG-lipid. Hence, the difference in
Zeta-potential between PEG5000-lipid and PEG2000-lipid was reasonable.
The liposomes with 0.75 mol% of PEG5000-lipid prepared using the
post-modiﬁcation method was almost equivalent to the liposomes
with 1.5 mol% of PEG5000-lipid prepared using the pre-modiﬁcation
method in terms of the charge-shielding effect [31,36]. Considering
that the distribution of PEG-lipid on the liposome contributes directly
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well supports those work since no clear differences were observed be-
tween the pre- and the post-modiﬁcation methods.3.2. Preservation stability of HSPC and PEG-lipid in liposomes
In order to examine the differences in physicochemical stability
arising from the use of different PEG-modiﬁcation methods, the pres-
ervation stability study was performed at 25 °C and 60% RH for
12 weeks with each CPT-11 liposomes (Pre and Post) modiﬁed with
PEG5000-lipid (Table 1). Fig. 1 (A) shows the results of the HSPC resid-
ual ratio and (B) the PEG5000-lipid residual ratio. As seen in Fig. 1 (A),
the degradation of HSPC gradually proceeded with time, and the
HSPC residual ratio ﬁnally reached to around 88% in both liposomes
after 12 weeks. Yet, no difference was observed between both. As
seen in Fig. 1 (B), about 25% of PEG5000-lipid degradation was ob-
served after 12 weeks in the pre-modiﬁcation method, whereas less
degradation was observed in the post-modiﬁcation method.
The degradation (hydrolysis) rate of PEG5000-lipid on the inside of li-
posomal membrane is expected to be higher than that of PEG5000-lipid
on that outside of liposomes, because the pH of internal aqueous
phase is kept considerably lowwhen conventional pH-gradientmethod
is applied. HSPC is considered to distribute equally on the inside and
outside of the liposomal bilayer in bothmethods. Therefore, it is reason-
able that no differences were observed in the HSPC degradation behav-
ior. On the other hand, clear differences in the preservation stability of
PEG5000-lipid were observed between both pre- and post-modiﬁcation
methods, which strongly suggest that the distribution of PEG5000-lipid
is completely different between both methods. That is, as mentioned
above, in the case of the pre-modiﬁcation method, PEG5000-lipid
would be distributed equally on the inner and outer surfaces of the(A) HSPC
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Fig. 1. Percent of HSPC and PEG-lipid residual ratio in PEGylated liposomes prepared using
PEG5000-lipid modiﬁed liposomes (A): remaining HSPC and (B): remaining PEG5000-lipid. PEliposomal membrane; therefore, the internal PEG5000-lipid is subjected
to hydrolysis due to the lowpHof the internal aqueous phase. However,
in the post-modiﬁcationmethod, all PEG5000-lipid would exclusively be
located on the outer surface of the liposomes, thus reducing hydrolysis.
The same behavior was observed in our recent research with other
drugs as well [30]. Since this ﬁnding was quite important, further
study was conducted using CPT-11 liposomes (Pre and Post) modiﬁed
with PEG2000-lipid (Table 1). Fig. 1 (C) shows the results for the HSPC
residual ratio and (D) the PEG2000-lipid residual ratio. As a result, it
was conﬁrmed that both HSPC and PEG2000-lipid degradations occurred
in the same manner, even though the PEGmolecular weight was lower
than Mw: 5000. These ﬁndings suggest that the PEGylated liposomes
prepared using the post-modiﬁcation method are superior to those
obtained using the pre-modiﬁcation method from the viewpoint of
preservation stability.3.3. Pharmacokinetics experiments of CPT-11 liposomes (Pre and Post)
The pharmacokinetics studies were performed with each CPT-11 li-
posomes (Pre and Post) modiﬁed with PEG5000-lipid [Fig. 2 (A)] and
PEG2000-lipid [Fig. 2 (B)], respectively. The total CPT-11 concentration
proﬁles in plasma after intravenous administration (30 mg/kg) are
shown. As seen in both ﬁgures, CPT-11 liposomes (Post) provided
higher total CPT-11 concentrations in plasma than CPT-11 liposomes
(Pre), not only (A) for PEG5000-lipid but also (B) for PEG2000-lipid. On
the other hand, no clear differencewas observed between PEG5000-lipid
and PEG2000-lipid. This means that both would have the same potential
pharmacokinetics when the same modiﬁcation method is used.
The pharmacokinetics parameters in a treatment group with
PEG5000-lipid of dosage shown in the above Fig. 2 (A) were analyzed.
The results are shown in Table 2. There were signiﬁcant differences in(B) PEG5000-lipid
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the pre- or post-modiﬁcation method after storage at 25 °C for 0, 4, 8, and 12 weeks.
G2000-lipid modiﬁed liposomes (C): remaining HSPC and (D): remaining PEG2000-lipid.
(A) PEG5000-lipid (B) PEG2000-lipid
Pre: Pre-modification method, Post: Post-modification methoda
Fig. 2. The drug-concentration proﬁles in plasma after intravenous administration of CPT-11 liposomes to male rats (30 mg/kg). CPT-11 liposomes modiﬁed with (A): PEG5000-lipid
and (B): PEG2000-lipid. CPT-11 liposomes prepared using the pre-modiﬁcation method (□) and PEGylated liposomes prepared using the post-modiﬁcation method (△). Data are
presented as mean±standard deviation (n=3).
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post-modiﬁcation methods (pb0.01), and more signiﬁcant differ-
ences were observed in the MRT and T1/2 (pb0.001). As a result, it
was conﬁrmed that CPT-11 liposomes (Post) signiﬁcantly allowed
CPT-11 to disappear more slowly (high values of MRT and T 1/2) and
to be maintained at a high concentration for a long time. In our recent
research, the same behavior was observed with other drugs [30].
Hence, it is considered that the present result is not related to the
drug itself but to the PEG-modiﬁcation method. These ﬁndings sug-
gest that the PEGylated liposomes prepared using the post-
modiﬁcation method are superior to those modiﬁed using the
pre-modiﬁcation method from the viewpoint of pharmacokinetics.3.4. In vitro CPT-11 release experiments in blood plasma of rats
To investigate further details, each CPT-11 liposomes (Pre and Post)
was incubated with rat plasma at 37 °C to evaluate the difference in the
CPT-11 release proﬁles. The results are shown for each CPT-11 liposomes
(Pre and Post) modiﬁed with PEG5000-lipid [Fig. 3 (A)] and PEG2000-lipid
[Fig. 3 (B)], respectively. As seen in both theﬁgures, therewere signiﬁcant
differences in the released CPT-11 ratio between liposomes prepared
using the pre- and post-modiﬁcation methods at 1 hour (pb0.01) and
2 h (pb0.001), respectively. This result indicates that CPT-11 liposomes
(Post) release the drug in rat plasma more slowly as compared to
CPT-11 liposomes (Pre). That is, it was ascertained that CPT-11 lipo-
somes (Post) could hold encapsulated CPT-11 for a longer time, com-
pared to CPT-11 liposomes (Pre). It was recently reported that the
drug-release rate from vesicles increased with increasing PEG con-
tents [32,37]. In the pre-modiﬁcation method, twice the amount ofTable 2
Pharmacokinetic parameters following intravenous administration of 30 mg/kg of both
CPT-11 liposomes to male rats. Data are presented as mean±standard deviation (n=6
for the pre-modiﬁcation method and n=5 for the post-modiﬁcation method).
Parameter Pre (n=6) Post (n=5)
AUC0–72 (mg·h/ml) 7607±588 9102±813⁎⁎
AUC0·inf (mg·h/ml) 7609±586 9111±817⁎⁎
MRT0·72 (h) 7.53±0.83 9.82±0.54⁎⁎⁎
MRT0·inf (h) 7.54±0.83 9.90±0.56⁎⁎⁎
T1/2 (h) 5.74±0.32 7.19±0.53⁎⁎⁎
CLtot (L/h/kg) 0.00396±0.00033 0.00331±0.00033⁎⁎
Pre: pre-modiﬁcation method, Post: post-modiﬁcation method.
⁎⁎: pb0.01, ⁎⁎⁎: pb0.001.PEG-lipid is required to achieve the same charge-shielding effect; there-
fore, membrane permeability would be higher in the pre-modiﬁcation
method than the post-modiﬁcation method. From this, it is considered
that the membrane permeability of CPT-11 liposomes (Pre) would be
higher than that of CPT-11 liposomes (Post) and that it would be a rea-
sonable. From the result of Fig. 1, the faster PEG-lipid degradation rate
might cause faster drug release in vitro and in vivo since hydrolysis of
PEG-lipid like lyso PEG-lipid and stearic acid might disturb the lipid
membrane. Although various unknown factors may still be involved in
this phenomenon, the present in vitro CPT-11 releasing study (Fig. 4)
is well consistent with the results of the pharmacokinetics study
(Fig. 3), in which CPT-11 liposomes (Post) showed prolonged circula-
tion time as compared to CPT-11 liposomes (Pre). Therefore, it is con-
sidered that the hypothesis shown above would be reasonable.3.5. In vivo antitumor effects with each CPT-11 liposomes (Pre and Post)
Through the various studies, it was conﬁrmed that the post-
modiﬁcation method showed prolonged circulation time and slower
drug-release proﬁle. However, there is no information regarding the
antitumor effects. Therefore, the in vivo antitumor effects with each
CPT-11 liposomes (Pre and Post) were compared using nude mice
subcutaneously implanted with human colon cancer cells (HT-29).
The results are shown for each CPT-11 liposomes (Pre and Post)
modiﬁed with PEG5000-lipid [Fig. 4 (A)] and PEG2000-lipid [Fig. 4
(B)], respectively. As seen in both ﬁgures, the tumor volume in the
control group gradually increased with time after tumor inoculation.
On the contrary, in all the administered groups, the increase in tumor
volume was suppressed as compared to that in the control group. To
compare the differences between the pre- and the post-modiﬁcation
methods, a suppressive effect on tumor growth was ﬁnally deter-
mined at 21 days, and the results are shown in Table 3. The tumor
volume in the control groups was an average of 1258 mm3 and
1286 mm3, respectively. As shown in Table 3, on comparing both
CPT-11 liposomes (Pre and Post) with the control groups, a signiﬁcant
low tumor weight was found (pb0.001). Comparison of CPT-11 lipo-
somes (Pre) and CPT-11 liposomes (Post) modiﬁed with PEG5000-lipid
showed that although the inhibition ratewas higher for CPT-11 liposomes
(Post), the difference was not statistical signiﬁcant. On the other hand,
comparisonof CPT-11 liposomes (Pre) andCPT-11 liposomes (Post)mod-
iﬁed with PEG2000-lipid showed that the inhibition rate was signiﬁcantly
higher in CPT-11 liposomes (Post) (pb0.01).
In general, the abnormal and leaky vasculature of tumor causes
enhanced permeability of liposomal drugs in tumors. Moreover, tumor
tissues usually lack effective lymphatic drainage. Therefore, PEGylated
(A) PEG5000-lipid (B) PEG2000-lipid
*
*
**: p < 0.01, ***: p < 0.001
* **
**
***
Pre: Pre-modification method, Post: Post-modification method
Fig. 3. CPT-11 release proﬁles in blood plasma from CPT-11 liposomes modiﬁed with (A): PEG5000-lipid and (B): PEG2000-lipid. CPT-11 liposomes prepared using the
pre-modiﬁcation method (□) and PEGylated liposomes prepared using the post-modiﬁcation method (△) after incubated at 37 °C for 0, 1, 2, and 4 h. Data are presented as
mean±standard deviation (n=3).
2906 K. Yoshino et al. / Biochimica et Biophysica Acta 1818 (2012) 2901–2907liposomes canbedrained through the leakyblood vessels andbe retained,
resulting in an increased accumulation of liposomal anticancer agents in
tumors. This phenomenon is called the enhanced permeation and reten-
tion (EPR) effect [38,39]. As described earlier, CPT-11 liposomes (Post)
showed prolonged circulation time (Fig. 2) and slower CPT-11 release
proﬁle (Fig. 3); therefore, it is considered that a large amount of CPT-11
could be delivered to the tumor cells through the leaky vasculature
owing to the EPR effects. These ﬁndings suggest that the PEGylated lipo-
somes prepared using the post-modiﬁcation method are superior to
those obtained using the pre-modiﬁcation method from the viewpoint
of the antitumor effect.
4. Conclusions
Through a series of comparative studies, it was shown that the
post-modiﬁcation method could markedly inhibit PEG-lipid degrada-
tion. Furthermore, a prolonged circulation time was observed with the5 9 14
(A) PEG5000-lipid
Pre: Pre-mod
Fig. 4. Suppressive effect on tumor growth after administration of CPT-11 liposomes (12.5 m
14. Data are presented as mean±standard deviation (n=10).post-modiﬁcation method. In addition, the CPT-11 release proﬁle in
blood plasma was restrained in the post-modiﬁcation method as com-
pared to the pre-modiﬁcation method. Moreover, the post-modiﬁcation
method showed a higher inhibition rate for tumor growth as compared
to the pre-modiﬁcation method. Using the post-modiﬁcation meth-
od, only half the amount of PEG-lipid is needed to have the same
charge-shielding effect as the pre-modiﬁcation method. Besides, the
CPT-11 release from liposomeswas slower since themembrane perme-
ability was decreased. As a result, it achieved the prolonged circulation
time and the higher antitumor effect. In addition, the same behaviors
were observed in all studies even though the PEG molecular weight
was lower.
In conclusion, CPT-11 liposomes prepared using the post-modiﬁcation
method can achieve higher preservation stability of PEG-lipid, prolonged
circulation time, sustained drug-release and higher antitumor effect with
only half the amount of PEG-lipid as compared to that needed in the
pre-modiﬁcation method. Furthermore, it was also demonstrated that5 9 14
(B) PEG2000-lipid
ification method, Post: Post-modification method
g/kg/dose) prepared using the pre- and post-modiﬁcation methods on days 0, 5, 9, and
Table 3
Inhibition rate for tumor growth at day 21. A 12.5 mg/kg/dose of CPT-11 liposome pre-
pared using pre- or post-modiﬁcation method was intravenously administered. Data
are presented as mean±standard deviation (n=10).
Group Tumor weight (g) Vs Cont. Vs Pre. Inhibition rate (%)
(Mean±S.D.)
Control 0.78±0.10 – – –
PEG5000 Pre 0.56±0.12 ⁎⁎⁎ – 27.8
PEG5000 Post 0.52±0.09 ⁎⁎⁎ N.S. 33.2
Control 0.72±0.12 – – –
PEG2000 Pre 0.51±0.05 ⁎⁎⁎ – 29.0
PEG2000 Post 0.43±0.06 ⁎⁎⁎ ⁎⁎ 40.7
Pre: pre-modiﬁcation method, Post: post-modiﬁcation method.
N.S.: not signiﬁcant, ⁎⁎: pb0.01, ⁎⁎⁎: pb0.001.
2907K. Yoshino et al. / Biochimica et Biophysica Acta 1818 (2012) 2901–2907PEG5000-lipid would be more desirable than PEG2000-lipid since it re-
quires much smaller amount of PEG-lipid to demonstrate the same
performances.
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